Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

This study is a prospective, multi-cohort, multicenter, open-label exploratory clinical trial. The primary study objective is to evaluate the pathologic complete response (PCR) of treatment of HR+/HER2-low breast cancer with neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab , including the incidences and types of adverse events. The secondary endpoints include event-free survival (EFS), residual cancer burden (RCB), and objective response rate (ORR).

Trial Details

NCT ID
NCT07383818
Phase
PHASE2
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab
  • Neoadjuvant Chemotherapy in Combination with Toripalimab
  • Neoadjuvant Chemotherapy
Locations (sample)
  • Harbin, China|45.75,126.65
  • Hefei, China|31.86389,117.28083
  • Shanghai, China|31.22222,121.45806
  • Xi'an, China|34.25833,108.92861
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Female patients aged 18-70 years old;
  • ECOG score is 0-1 points;
  • Histologically or pathologically confirmed invasive breast cancer, meeting the following criteria simultaneously: Invasive breast cancer staged as …
  • Function levels of major organs must meet the required criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →